Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study

• Published in: Clinical pharmacology in drug development Vol. 7; no. 4; pp. 408 - 421
• Main Authors: Hunt, Hazel, Donaldson, Kirsteen, Strem, Mark, Zann, Vanessa, Leung, Pui, Sweet, Suzanne, Connor, Alyson, Combs, Dan, Belanoff, Joseph
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2018; John Wiley and Sons Inc
• Subjects: Administration, Oral; Area Under Curve; CORT125134; Cushing syndrome; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Drug Administration Schedule; Female; First‐in‐Human; Glucocorticoid; Half-Life; Healthy Volunteers; Humans; Male; Original Manuscript; Pharmacokinetics; Pharmacological effect; Pharmacology; Receptors, Glucocorticoid - antagonists & inhibitors; Small Molecule Libraries - administration & dosage; Small Molecule Libraries - adverse effects; Small Molecule Libraries - pharmacokinetics; First-in-Human; CORT125134; Glucocorticoid; Pharmacological effect; Cushing syndrome
• ISSN: 2160-763X; 2160-7648; 2160-7648
• DOI: 10.1002/cpdd.389

CORT125134 is an orally active, high‐affinity, selective antagonist of the glucocorticoid receptor that is being developed for indications that may benefit from the modulation of cortisol activity. This first‐in‐human study was conducted to evaluate the dose‐related safety, tolerability, pharmacokinetics and pharmacological effects of CORT125134 and its active metabolite CORT125201. Eighty‐one healthy male or female subjects received a single dose of 5 to 500 mg CORT125134 or matching placebo across 9 cohorts; 1 cohort received 150 mg CORT125134 after a high‐fat breakfast; and 46 subjects received 50 to 500 mg CORT125134 or matching placebo once daily for up to 14 days across 4 cohorts. CORT125134 was well tolerated at doses up to 250 mg per day for 14 days. CORT125134 was absorbed rapidly and eliminated with a mean half‐life ranging from 11 to 19 hours. Steady state was achieved by day 7. Exposure increased in a greater than proportional manner, particularly at lower doses. Exposure to CORT125201 at steady state was less than 5% that of parent CORT125134. Evidence for the desired pharmacological effect (glucocorticoid receptor antagonism) was demonstrated by the ability of CORT125134 to prevent several effects of the glucocorticoid receptor agonist prednisone.